|
1CDK
CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT (E.C.2.7.1.37) (PROTEIN KINASE A) COMPLEXED WITH PROTEIN KINASE INHIBITOR PEPTIDE FRAGMENT 5-24 (PKI(5-24) ISOELECTRIC VARIANT CA) AND MN2+ ADENYLYL IMIDODIPHOSPHATE (MNAMP-PNP) AT PH 5.6 AND 7C AND 4C
Deposited 1994-07-04
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain I
6–25(20 aa)
|
Not recorded
|
MN MANGANESE (II) ION × 2
ANP PHOSPHOAMINOPHOSPHONIC ACID-ADENYLATE ESTER × 1
MYR MYRISTIC ACID × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 5.6;280 K;pH 5.6, temperature 280K
|
Resolution 2.00 Å
|
|
1CDK
CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT (E.C.2.7.1.37) (PROTEIN KINASE A) COMPLEXED WITH PROTEIN KINASE INHIBITOR PEPTIDE FRAGMENT 5-24 (PKI(5-24) ISOELECTRIC VARIANT CA) AND MN2+ ADENYLYL IMIDODIPHOSPHATE (MNAMP-PNP) AT PH 5.6 AND 7C AND 4C
Deposited 1994-07-04
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain J
6–25(20 aa)
|
Not recorded
|
MN MANGANESE (II) ION × 2
ANP PHOSPHOAMINOPHOSPHONIC ACID-ADENYLATE ESTER × 1
MYR MYRISTIC ACID × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 5.6;280 K;pH 5.6, temperature 280K
|
Resolution 2.00 Å
|
|
1CMK
CRYSTAL STRUCTURES OF THE MYRISTYLATED CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE REVEAL OPEN AND CLOSED CONFORMATIONS
Deposited 1993-11-18
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 12
PDB declaration: dodecameric
|
Chain I
6–27(22 aa)
|
Not recorded
|
MYR MYRISTIC ACID × 6
IOD IODIDE ION × 12
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 2.90 Å
|
|
1CTP
STRUCTURE OF THE MAMMALIAN CATALYTIC SUBUNIT OF CAMP-DEPENDENT PROTEIN KINASE AND AN INHIBITOR PEPTIDE DISPLAYS AN OPEN CONFORMATION
Deposited 1993-04-08
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 4
PDB declaration: tetrameric
|
Chain I
6–25(20 aa)
|
Non-standard monomer:Yes (specific site not provided by mmCIF)
|
MYR MYRISTIC ACID × 2
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 2.90 Å
|
|
1XH4
Crystal Structures of Protein Kinase B Selective Inhibitors in Complex with Protein Kinase A and Mutants
Deposited 2004-09-17
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain B
5–24(20 aa)
Fragment:PKI(residues 5-24)
|
Not recorded
|
R69 N-[4-({4-[5-(DIMETHYLAMINO)-2-HYDROXYBENZOYL]BENZOYL}AMINO)AZEPAN-3-YL]ISONICOTINAMIDE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 6.4;278 K;LiCl, MesBisTris, methanol, MEGA-8, pH 6.4, VAPOR DIFFUSION, HANGING DROP, temperature 278K
|
Resolution 2.45 Å
R-free 0.242
|
|
1XH5
Crystal Structures of Protein Kinase B Selective Inhibitors in Complex with Protein Kinase A and Mutants
Deposited 2004-09-17
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain B
5–24(20 aa)
Fragment:PKI(residues 5-24)
|
Not recorded
|
R68 N-{4-[(4-{3-[(2R)-3,3-DIMETHYLPIPERIDIN-2-YL]-2-FLUORO-6-HYDROXYBENZOYL}BENZOYL)AMINO]AZEPAN-3-YL}ISONICOTINAMIDE × 1
BU3 (R,R)-2,3-BUTANEDIOL × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 6.4;278 K;LiCl, MesBisTris, methanol, MEGA-8, pH 6.4, VAPOR DIFFUSION, HANGING DROP, temperature 278K
|
Resolution 2.05 Å
R-free 0.236
|
|
1XH6
Crystal Structures of Protein Kinase B Selective Inhibitors in Complex with Protein Kinase A and Mutants
Deposited 2004-09-17
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain B
5–24(20 aa)
Fragment:PKI(residues 5-24)
|
Not recorded
|
R94 N-(4-{[4-(2-HYDROXY-5-PIPERIDIN-1-YLBENZOYL)BENZOYL]AMINO}AZEPAN-3-YL)ISONICOTINAMIDE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 6.4;278 K;LiCl, MesBisTris, methanol, MEGA-8, pH 6.4, VAPOR DIFFUSION, HANGING DROP, temperature 278K
|
Resolution 1.90 Å
R-free 0.249
|
|
1XH7
Crystal Structures of Protein Kinase B Selective Inhibitors in Complex with Protein Kinase A and Mutants
Deposited 2004-09-17
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain B
5–24(20 aa)
Fragment:PKI(residues 5-24)
|
Not recorded
|
R96 N-[4-({4-[5-(3,3-DIMETHYLPIPERIDIN-1-YL)-2-HYDROXYBENZOYL]BENZOYL}AMINO)AZEPAN-3-YL]ISONICOTINAMIDE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 6.4;278 K;LiCl, MesBisTris, methanol, MEGA-8, pH 6.4, VAPOR DIFFUSION, HANGING DROP, temperature 278K
|
Resolution 2.47 Å
R-free 0.254
|
|
1XH8
Crystal Structures of Protein Kinase B Selective Inhibitors in Complex with Protein Kinase A and Mutants
Deposited 2004-09-17
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain B
5–24(20 aa)
Fragment:PKI(residues 5-24)
|
Not recorded
|
R55 N-[4-({4-[5-(4,4-DIMETHYLPIPERIDIN-1-YL)-2-HYDROXYBENZOYL]BENZOYL}AMINO)AZEPAN-3-YL]ISONICOTINAMIDE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 6.4;278 K;LiCl, MesBisTris, methanol, MEGA-8, pH 6.4, VAPOR DIFFUSION, HANGING DROP, temperature 278K
|
Resolution 1.60 Å
R-free 0.236
|
|
1XH9
Crystal Structures of Protein Kinase B Selective Inhibitors in Complex with Protein Kinase A and Mutants
Deposited 2004-09-17
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain B
5–24(20 aa)
Fragment:PKI(residues 5-24)
|
Not recorded
|
R69 N-[4-({4-[5-(DIMETHYLAMINO)-2-HYDROXYBENZOYL]BENZOYL}AMINO)AZEPAN-3-YL]ISONICOTINAMIDE × 1
BU3 (R,R)-2,3-BUTANEDIOL × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 6.4;278 K;LiCl, MesBisTris, methanol, MEGA-8, pH 6.4, VAPOR DIFFUSION, HANGING DROP, temperature 278K
|
Resolution 1.64 Å
R-free 0.199
|
|
1XHA
Crystal Structures of Protein Kinase B Selective Inhibitors in Complex with Protein Kinase A and Mutants
Deposited 2004-09-17
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain B
5–24(20 aa)
Fragment:PKI(residues 5-24)
|
Not recorded
|
R68 N-{4-[(4-{3-[(2R)-3,3-DIMETHYLPIPERIDIN-2-YL]-2-FLUORO-6-HYDROXYBENZOYL}BENZOYL)AMINO]AZEPAN-3-YL}ISONICOTINAMIDE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 6.4;278 K;LiCl, MesBisTris, methanol, MEGA-8, pH 6.4, VAPOR DIFFUSION, HANGING DROP, temperature 278K
|
Resolution 2.46 Å
R-free 0.272
|
|
1YDR
STRUCTURE OF CAMP-DEPENDENT PROTEIN KINASE, ALPHA-CATALYTIC SUBUNIT IN COMPLEX WITH H7 PROTEIN KINASE INHIBITOR 1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE
Deposited 1996-07-24
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain I
5–24(20 aa)
|
Not recorded
|
IQP 1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 6.5;15 % METHANOL, 70 MILLIMOLAR SODIUM SULFATE, 20 MILLIMOLAR MES-BIS-TRIS PH 6.5, 279K USING HANGING DROP DIFFUSION., vapor diffusion - hanging drop
|
Resolution 2.20 Å
|
|
2C1A
Structure of cAMP-dependent protein kinase complexed with Isoquinoline-5-sulfonic acid (2-(2-(4-chlorobenzyloxy)ethylamino) ethyl)amide
Deposited 2005-09-12
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain I
5–24(20 aa)
|
Not recorded
|
I5S ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY)ETHYLAMINO)ETHYL)AMIDE × 1
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 1.95 Å
R-free 0.230
|
|
2C1B
Structure of cAMP-dependent protein kinase complexed with (4R,2S)-5'-(4-(4-Chlorobenzyloxy)pyrrolidin-2-ylmethanesulfonyl)isoquinoline
Deposited 2005-09-12
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain I
5–24(20 aa)
|
Not recorded
|
CQP (4R,2S)-5'-(4-(4-CHLOROBENZYLOXY)PYRROLIDIN-2-YLMETHANESULFONYL)ISOQUINOLINE × 1
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 2.00 Å
R-free 0.211
|
|
2JDS
Structure of cAMP-dependent protein kinase complexed with A-443654
Deposited 2007-01-12
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain I
5–24(20 aa)
Fragment:RESIDUES 5-24
|
Not recorded
|
L20 (2S)-1-(1H-INDOL-3-YL)-3-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE × 1
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 2.00 Å
R-free 0.272
|
|
2JDT
Structure of PKA-PKB chimera complexed with ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY) ETHYLAMINO)ETHYL)AMIDE
Deposited 2007-01-12
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain I
5–24(20 aa)
Fragment:RESIDUES 5-24
|
Not recorded
|
I5S ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY)ETHYLAMINO)ETHYL)AMIDE × 1
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 2.15 Å
R-free 0.259
|
|
2JDV
Structure of PKA-PKB chimera complexed with A-443654
Deposited 2007-01-12
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain I
5–24(20 aa)
Fragment:RESIDUES 5-24
|
Not recorded
|
L20 (2S)-1-(1H-INDOL-3-YL)-3-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE × 1
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 2.08 Å
R-free 0.276
|
|
2L1L
NMR Solution Structure of the Phi0 PKI NES Peptide in Complex with CRM1-RanGTP
Deposited 2010-07-29
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain A
30–54(25 aa)
|
Not recorded
|
No recorded non-water small molecule
|
SOLUTION NMR
NMR measurement conditions
pH 6.8;298 K;Ionic strength (raw mmCIF value) 50;Pressure ambient
NMR sample composition
200 uM [U-13C; U-15N; U-2H; ILV-1H] Phi0 PKI-NES-1, 200 uM [U-13C; U-15N; U-2H; ILV-1H, Ala-1H/12C/14N] Phi0 PKI-NES-2, 90% H2O/10% D2O | 90% H2O/10% D2O
|
Resolution not provided
|
|
2UVX
Structure of PKA-PKB chimera complexed with 7-azaindole
Deposited 2007-03-15
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain I
5–24(20 aa)
Fragment:RESIDUES 5-24
|
Not recorded
|
GVH 1H-PYRROLO[2,3-B]PYRIDINE × 1
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 2.00 Å
R-free 0.237
|
|
2UVY
Structure of PKA-PKB chimera complexed with methyl-(4-(9H-purin-6-yl)- benzyl)-amine
Deposited 2007-03-15
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain I
5–24(20 aa)
Fragment:RESIDUES 5-24
|
Not recorded
|
GVI N-METHYL-1-[4-(9H-PURIN-6-YL)PHENYL]METHANAMINE × 1
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 1.95 Å
R-free 0.253
|
|
2UVZ
Structure of PKA-PKB chimera complexed with C-Phenyl-C-(4-(9H-purin-6- yl)-phenyl)-methylamine
Deposited 2007-03-15
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain I
5–24(20 aa)
Fragment:RESIDUES 5-24
|
Not recorded
|
GVJ (S)-1-PHENYL-1-[4-(9H-PURIN-6-YL)PHENYL]METHANAMINE × 1
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 1.94 Å
R-free 0.245
|
|
2UW0
Structure of PKA-PKB chimera complexed with 6-(4-(4-(4-Chloro-phenyl) -piperidin-4-yl)-phenyl)-9H-purine
Deposited 2007-03-15
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain I
5–24(20 aa)
Fragment:RESIDUES 5-24
|
Not recorded
|
GVK 6-{4-[4-(4-CHLOROPHENYL)PIPERIDIN-4-YL]PHENYL}-9H-PURINE × 1
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 2.00 Å
R-free 0.248
|
|
2UW3
Structure of PKA-PKB chimera complexed with 5-methyl-4-phenyl-1H- pyrazole
Deposited 2007-03-19
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain I
5–24(20 aa)
Fragment:RESIDUES 5-24
|
Not recorded
|
GVG 3-METHYL-4-PHENYL-1H-PYRAZOLE × 1
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 2.19 Å
R-free 0.252
|
|
2UW4
Structure of PKA-PKB chimera complexed with 2-(4-(5-methyl-1H-pyrazol- 4-yl)-phenyl)-ethylamine
Deposited 2007-03-19
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain I
5–24(20 aa)
Fragment:RESIDUES 5-24
|
Not recorded
|
L15 2-[4-(3-METHYL-1H-PYRAZOL-4-YL)PHENYL]ETHANAMINE × 1
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 2.00 Å
R-free 0.274
|
|
2UW5
Structure of PKA-PKB chimera complexed with (R)-2-(4-chloro-phenyl)- 2-(4-1H-pyrazol-4-yl)-phenyl)-ethylamine
Deposited 2007-03-19
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain I
5–24(20 aa)
Fragment:RESIDUES 5-24
|
Not recorded
|
GVN (2R)-2-(4-CHLOROPHENYL)-2-[4-(1H-PYRAZOL-4-YL)PHENYL]ETHANAMINE × 1
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 2.14 Å
R-free 0.259
|
|
2UW6
Structure of PKA-PKB chimera complexed with (S)-2-(4-chloro-phenyl)- 2-(4-1H-pyrazol-4-yl)-phenyl)-ethylamine
Deposited 2007-03-19
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain I
5–24(20 aa)
Fragment:RESIDUES 5-24
|
Not recorded
|
GVO (2S)-2-(4-CHLOROPHENYL)-2-[4-(1H-PYRAZOL-4-YL)PHENYL]ETHANAMINE × 1
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 2.23 Å
R-free 0.244
|
|
2UW7
Structure of PKA-PKB chimera complexed with 4-(4-chloro-phenyl)-4-(4- (1H-pyrazol-4-yl)-phenyl)-piperidine
Deposited 2007-03-19
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain I
5–24(20 aa)
Fragment:RESIDUES 5-24
|
Not recorded
|
GVP 4-(4-CHLOROPHENYL)-4-[4-(1H-PYRAZOL-4-YL)PHENYL]PIPERIDINE × 1
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 2.10 Å
R-free 0.318
|
|
2UW8
Structure of PKA-PKB chimera complexed with 2-(4-chloro-phenyl)-2- phenyl-ethylamine
Deposited 2007-03-19
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain I
5–24(20 aa)
Fragment:RESIDUES 5-24
|
Not recorded
|
GVQ (2R)-2-(4-CHLOROPHENYL)-2-PHENYLETHANAMINE × 1
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 2.00 Å
R-free 0.233
|
|
2VNW
Structure of PKA-PKB chimera complexed with (1-(9H-Purin-6-yl) piperidin-4-yl)methanamine
Deposited 2008-02-08
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain I
6–25(20 aa)
Fragment:RESIDUES 6-25
|
Not recorded
|
M01 1-[1-(9H-purin-6-yl)piperidin-4-yl]methanamine × 1
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 2.09 Å
R-free 0.247
|
|
2VNY
Structure of PKA-PKB chimera complexed with (1-(9H-Purin-6-yl) piperidin-4-yl)amine
Deposited 2008-02-08
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain I
6–25(20 aa)
Fragment:RESIDUES 6-25
|
Not recorded
|
M02 1-(9H-purin-6-yl)piperidin-4-amine × 1
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 1.96 Å
R-free 0.292
|
|
2VO0
Structure of PKA-PKB chimera complexed with C-(4-(4-Chlorophenyl)-1-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)piperidin-4-yl)methylamine
Deposited 2008-02-08
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain I
6–25(20 aa)
Fragment:RESIDUES 6-25
|
Not recorded
|
CL CHLORIDE ION × 1
MRD (4R)-2-METHYLPENTANE-2,4-DIOL × 1
EDO 1,2-ETHANEDIOL × 2
M03 1-[4-(4-chlorophenyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-yl]methanamine × 2
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 1.94 Å
R-free 0.216
|
|
2VO3
Structure of PKA-PKB chimera complexed with C-(4-(4-Chlorophenyl)-1-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)piperidin-4-yl)methylamine
Deposited 2008-02-08
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain I
6–25(20 aa)
Fragment:RESIDUES 6-25
|
Not recorded
|
CL CHLORIDE ION × 1
M04 1-[4-(4-chlorobenzyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-yl]methanamine × 1
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 1.98 Å
R-free 0.246
|
|
2VO6
Structure of PKA-PKB chimera complexed with 4-(4-Chlorobenzyl)-1-(7H- pyrrolo(2,3-d)pyrimidin-4-yl)piperidin-4-ylamine
Deposited 2008-02-08
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain I
6–25(20 aa)
Fragment:RESIDUES 6-25
|
Not recorded
|
CL CHLORIDE ION × 1
M05 4-(4-chlorobenzyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-aminium × 1
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 1.97 Å
R-free 0.229
|
|
2VO7
Structure of PKA complexed with 4-(4-Chlorobenzyl)-1-(7H-pyrrolo(2,3- d)pyrimidin-4-yl)piperidin-4-ylamine
Deposited 2008-02-08
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain I
6–25(20 aa)
Fragment:RESIDUES 6-25
|
Not recorded
|
M05 4-(4-chlorobenzyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-aminium × 2
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 1.98 Å
R-free 0.241
|
|
3AMA
Protein kinase A sixfold mutant model of Aurora B with inhibitor JNJ-7706621
Deposited 2010-08-18
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain B
6–25(20 aa)
Fragment:UNP residues 6-25
|
Not recorded
|
SKE 4-({5-amino-1-[(2,6-difluorophenyl)carbonyl]-1H-1,2,4-triazol-3-yl}amino)benzenesulfonamide × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7.5;277 K;25mM Tris-HCl, 25mM NaCl, 1.5mM octanoyl-N-methylglucamide, 1mM (5-24)-PKI,12-20% (v/v) methanol, 2-methyl 2,4-pentanediol, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 1.75 Å
R-free 0.223
|
|
3AMB
Protein kinase A sixfold mutant model of Aurora B with inhibitor VX-680
Deposited 2010-08-18
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain B
6–25(20 aa)
Fragment:UNP residues 6-25
|
Not recorded
|
VX6 CYCLOPROPANECARBOXYLIC ACID {4-[4-(4-METHYL-PIPERAZIN-1-YL)-6-(5-METHYL-2H-PYRAZOL-3-YLAMINO)-PYRIMIDIN-2-YLSULFANYL]-PHENYL}-AMIDE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7.5;277 K;25mM Tris-HCl, 25mM NaCl, 1.5mM octanoyl-N-methylglucamide, 1mM (5-24)-PKI, 12-20% (v/v) methanol, 2-methyl-2,4-pentanediol 30%, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 2.25 Å
R-free 0.256
|
|
3L9L
Crystal structure of pka with compound 36
Deposited 2010-01-05
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain C
6–25(20 aa)
Fragment:sequence database residues 6-25
|
Not recorded
|
L9L 5-[2-({(2S)-2-amino-3-[4-(trifluoromethyl)phenyl]propyl}amino)-1,3-thiazol-5-yl]-1,3-dihydro-2H-indol-2-one × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 8;277 K;1.0 M LiCl, 20-30% PEG6K, pH 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 2.00 Å
R-free 0.262
|
|
3L9L
Crystal structure of pka with compound 36
Deposited 2010-01-05
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain D
6–25(20 aa)
Fragment:sequence database residues 6-25
|
Not recorded
|
L9L 5-[2-({(2S)-2-amino-3-[4-(trifluoromethyl)phenyl]propyl}amino)-1,3-thiazol-5-yl]-1,3-dihydro-2H-indol-2-one × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 8;277 K;1.0 M LiCl, 20-30% PEG6K, pH 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 2.00 Å
R-free 0.262
|
|
3L9M
Crystal structure of PKAB3 (pka triple mutant V123A, L173M, Q181K) with compound 18
Deposited 2010-01-05
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain C
6–25(20 aa)
Fragment:sequence database residues 6-25
|
Not recorded
|
L9M (2S)-N~1~-[5-(3-methyl-1H-indazol-5-yl)-1,3,4-thiadiazol-2-yl]-3-(4-methylphenyl)propane-1,2-diamine × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 8;277 K;1.0 M LiCl, 20-30% PEG6K, pH 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 1.90 Å
R-free 0.270
|
|
3L9M
Crystal structure of PKAB3 (pka triple mutant V123A, L173M, Q181K) with compound 18
Deposited 2010-01-05
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain D
6–25(20 aa)
Fragment:sequence database residues 6-25
|
Not recorded
|
L9M (2S)-N~1~-[5-(3-methyl-1H-indazol-5-yl)-1,3,4-thiadiazol-2-yl]-3-(4-methylphenyl)propane-1,2-diamine × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 8;277 K;1.0 M LiCl, 20-30% PEG6K, pH 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 1.90 Å
R-free 0.270
|
|
3L9N
crystal structure of PKAB3 (pka triple mutant V123A, L173M, Q181K) with compound 27
Deposited 2010-01-05
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain C
6–25(20 aa)
Fragment:sequence database residues 6-25
|
Not recorded
|
L9N (2S)-N~1~-[5-(1H-indazol-5-yl)-1,3,4-thiadiazol-2-yl]-3-(4-methylphenyl)propane-1,2-diamine × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 8;277 K;1.0 M LiCl,
20-30% PEG6K, pH 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 2.00 Å
R-free 0.257
|
|
3MVJ
Human cyclic AMP-dependent protein kinase PKA inhibitor complex
Deposited 2010-05-04
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain J
6–25(20 aa)
|
Not recorded
|
XFE (3R)-1-(5-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrrolidin-3-amine × 1
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 2.49 Å
R-free 0.304
|
|
3MVJ
Human cyclic AMP-dependent protein kinase PKA inhibitor complex
Deposited 2010-05-04
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain K
6–25(20 aa)
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 2.49 Å
R-free 0.304
|
|
3MVJ
Human cyclic AMP-dependent protein kinase PKA inhibitor complex
Deposited 2010-05-04
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain I
6–25(20 aa)
|
Not recorded
|
XFE (3R)-1-(5-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrrolidin-3-amine × 1
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 2.49 Å
R-free 0.304
|
|
3NX8
human cAMP dependent protein kinase in complex with phenol
Deposited 2010-07-13
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain B
6–25(20 aa)
Fragment:residues 5-24
|
Not recorded
|
IPH PHENOL × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 6.9;277 K;5 mM MES, 5mM BisTris-propane, 75mM LiCl, 1mM DTT, 0.1 mM EDTA equilibrated against water/ethanol, pH 6.9, VAPOR DIFFUSION, SITTING DROP, temperature 277K
|
Resolution 2.00 Å
R-free 0.288
|
|
3OOG
human cAMP-dependent protein kinase in complex with a small fragment
Deposited 2010-08-31
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain B
6–25(20 aa)
Fragment:residues 5-24
|
Not recorded
|
YTP 1-(4-hydroxy-3-methylphenyl)ethanone × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 6.9;277 K;5 mM MES, 5mM BisTris-propane, 75mM LiCl, 1mM DTT, 0.1 mM EDTA equilibrated against water/ethanol, pH 6.9, VAPOR DIFFUSION, SITTING DROP, temperature 277K
|
Resolution 2.00 Å
R-free 0.276
|
|
3OVV
Human cAMP-dependent protein kinase in complex with an inhibitor
Deposited 2010-09-17
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain B
6–25(20 aa)
Fragment:residues 5-24
|
Not recorded
|
1SB N'-[(1E)-(4-hydroxyphenyl)methylidene]-2-(3-methoxyphenyl)acetohydrazide × 1
BUD (2S,3S)-butane-2,3-diol × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 6.9;277 K;5 mM MES, 5mM BisTris-propane, 75mM LiCl, 1mM DTT, 0.1 mM EDTA, equilibrated against water/ethanol, pH 6.9, VAPOR DIFFUSION, SITTING DROP, temperature 277K
|
Resolution 1.58 Å
R-free 0.232
|
|
3OWP
Human cAMP-dependent protein kinase in complex with an inhibitor
Deposited 2010-09-20
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain B
6–25(20 aa)
Fragment:residues 5-24
|
Not recorded
|
2SB (2S)-2-amino-N'-[(1E)-(3-bromo-4-hydroxyphenyl)methylidene]-2-phenylethanehydrazide × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 6.9;277 K;5 mM MES, 5mM BisTris-propane, 75mM LiCl, 1mM DTT, 0.1 mM EDTA, equilibrated against water/ethanol, pH 6.9, VAPOR DIFFUSION, SITTING DROP, temperature 277K
|
Resolution 1.88 Å
R-free 0.211
|
|
3OXT
Human cAMP-dependent protein kinase in complex with an inhibitor
Deposited 2010-09-22
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain B
6–25(20 aa)
Fragment:residues 5-24
|
Not recorded
|
3SB (2S)-2-amino-N'-[(1E)-(2,4-dihydroxy-6-methylphenyl)methylidene]-2-phenylethanehydrazide × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 6.9;277 K;5mM MES, 5mM BisTris-propane, 75mM LiCl, 1mM DTT, 0.1 mM EDTA, equilibrated against water/ethanol, pH 6.9, VAPOR DIFFUSION, SITTING DROP, temperature 277K
|
Resolution 2.20 Å
R-free 0.239
|
|
3P0M
Human cAMP-dependent protein kinase in complex with an inhibitor
Deposited 2010-09-29
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain B
6–25(20 aa)
Fragment:residues 5-24
|
Not recorded
|
4SB (2R)-4-amino-N'-[(1E)-(3-bromo-4-hydroxyphenyl)methylidene]-2-phenylbutanehydrazide × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 6.9;277 K;5mM MES, 5mM BisTris-propane, 75mM LiCl, 1mM DTT, 0.1mM EDTA, equilibrated against water/ethanol, pH 6.9, VAPOR DIFFUSION, SITTING DROP, temperature 277K
|
Resolution 2.03 Å
R-free 0.205
|
|
3POO
human cAMP-dependent protein kinase in complex with an inhibitor
Deposited 2010-11-23
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain B
6–25(20 aa)
Fragment:unp residues 6-25
|
Not recorded
|
S69 N'-[(E)-(2,4-dihydroxy-6-methylphenyl)methylidene]-2-(3-methoxyphenyl)acetohydrazide × 1
BUD (2S,3S)-butane-2,3-diol × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 6.9;289 K;5mM MES, 5mM BisTris-propane, 75mM LiCl, 1ml DTT, 0.1mM EDTA equilibrated against water/ethanol, pH 6.9, VAPOR DIFFUSION, SITTING DROP, temperature 277K, temperature 289K
|
Resolution 1.60 Å
R-free 0.212
|
|
3VQH
Bromine SAD partially resolves multiple binding modes for PKA inhibitor H-89
Deposited 2012-03-23
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain B
6–25(20 aa)
Fragment:UNP resodues 6-25
|
Not recorded
|
IQB N-[2-(4-BROMOCINNAMYLAMINO)ETHYL]-5-ISOQUINOLINE SULFONAMIDE × 1
MPD (4S)-2-METHYL-2,4-PENTANEDIOL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 6.9;277 K;10mg/ml protein, 25mM BisTris/MES pH6.9, 50mM KCl, 1.5mM octanoyl-N-methylglucamide, 1mM Protein kinase inhibitor peptide, 5mM H-89 in MeOH', VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 1.95 Å
R-free 0.234
|
|
3WYG
Crystal structure of Xpo1p-PKI-Gsp1p-GTP complex
Deposited 2014-08-26
|
Different oligomeric state
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 3
PDB declaration: trimeric
|
Chain D
1–76(76 aa)
|
Mutation:S35L
|
GTP GUANOSINE-5'-TRIPHOSPHATE × 1
MG MAGNESIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7.7;0.1M TRIS, 15% PEG20000, PH 7.7, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 293K
|
Resolution 2.15 Å
R-free 0.220
|
|
4AXA
Structure of PKA-PKB chimera complexed with (1S)-2-amino-1-(4- chlorophenyl)-1-(4-(1H-pyrazol-4-yl)phenyl)ethan-1-ol
Deposited 2012-06-12
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain I
6–25(20 aa)
Fragment:RESIDUES 6-25
|
Not recorded
|
RKD (2S)-2-(4-chlorophenyl)-2-hydroxy-2-[4-(1H-pyrazol-4-yl)phenyl]ethanaminium × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.5;pH 6.5
|
Resolution 1.90 Å
R-free 0.256
|
|
4IE9
Bovine PKA C-alpha in complex with 3-pyridylmethyl-5-methyl-1H-pyrazole-3-carboxylate
Deposited 2012-12-13
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain I
6–25(20 aa)
Fragment:UNP residues 6-25
|
Not recorded
|
PZX pyridin-3-ylmethyl 5-methyl-1H-pyrazole-3-carboxylate × 1
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION;pH 6.4;278 K;pH 6.4, VAPOR DIFFUSION, temperature 278K
|
Resolution 1.92 Å
R-free 0.232
|
|
4IJ9
Bovine PKA C-alpha in complex with 2-[[5-(4-pyridyl)-1H-1,2,4-triazol-3-yl]sulfanyl]-1-(2-thiophenyl)ethanone
Deposited 2012-12-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain I
6–25(20 aa)
Fragment:UNP residues 6-25
|
Not recorded
|
PTV 2-[[5-(4-pyridyl)-1H-1,2,4-triazol-3-yl]sulfanyl]-1-(2-thiophenyl)ethanone × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 6.4;278 K;LiCl, MesBisTris, methanol, pH 6.4, VAPOR DIFFUSION, HANGING DROP, temperature 278K
|
Resolution 2.55 Å
R-free 0.247
|
|
4O21
Product complex of metal-free PKAc, ATP-gamma-S and SP20.
Deposited 2013-12-16
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain S
6–25(20 aa)
Fragment:UNP residues 6-25
|
Mutation:N20A, A21S
Non-standard monomer:Yes (specific site not provided by mmCIF)
|
ADP ADENOSINE-5'-DIPHOSPHATE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 6.5;277 K;100 mM MES pH 6.5, 5 mM DTT, 15-20% PEG 4000., VAPOR DIFFUSION, SITTING DROP, temperature 277K
|
Resolution 1.95 Å
R-free 0.215
|
|
4O22
Binary complex of metal-free PKAc with SP20.
Deposited 2013-12-16
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain S
6–25(20 aa)
Fragment:UNP residues 6-25
|
Mutation:N20A, A21S
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 6.5;277 K;100 mM MES pH 6.5, 5 mM DTT, 15-20% PEG 3350., VAPOR DIFFUSION, SITTING DROP, temperature 277K
|
Resolution 1.70 Å
R-free 0.219
|
|
4UJ1
Protein Kinase A in complex with an Inhibitor
Deposited 2015-04-07
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain B
6–25(20 aa)
Fragment:UNP RESIDUES 6-25
|
Not recorded
|
NVX 7-[(3S,4R)-4-(3-chlorophenyl)carbonylpyrrolidin-3-yl]-3H-quinazolin-4-one × 1
MPD (4S)-2-METHYL-2,4-PENTANEDIOL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;277 K;10MG/ML PROTEIN, 25MM BISTRIS/MES PH6.9, 50MM KCL, 1.5MM OCTANOYL-N-METHYLGLUCAMIDE, 1MM PROTEIN KINASE INHIBITOR PEPTIDE, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 277K
|
Resolution 1.77 Å
R-free 0.201
|
|
4UJ2
Protein Kinase A in complex with an Inhibitor
Deposited 2015-04-07
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain B
6–25(20 aa)
Fragment:UNP RESIDUES 6-25
|
Not recorded
|
NVV 7-[(3S,4R)-4-(3-iodanylphenyl)carbonylpyrrolidin-3-yl]-3H-quinazolin-4-one × 1
MPD (4S)-2-METHYL-2,4-PENTANEDIOL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;277 K;10MG/ML PROTEIN, 25MM BISTRIS/MES PH6.9, 50MM KCL, 1.5MM OCTANOYL-N-METHYLGLUCAMIDE, 1MM PROTEIN KINASE INHIBITOR PEPTIDE, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 277K
|
Resolution 2.02 Å
R-free 0.209
|
|
4UJ9
Protein Kinase A in complex with an Inhibitor
Deposited 2015-04-09
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain B
6–25(20 aa)
|
Not recorded
|
S3N 7-[(3S,4R)-4-[4-(trifluoromethyl)phenyl]carbonylpyrrolidin-3-yl]-3H-quinazolin-4-one × 1
MPD (4S)-2-METHYL-2,4-PENTANEDIOL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;277 K;10MG/ML PROTEIN, 25MM BISTRIS/MES PH6.9, 50MM KCL, 1.5MM OCTANOYL-N-METHYLGLUCAMIDE, 1MM PROTEIN KINASE INHIBITOR PEPTIDE, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 277K
|
Resolution 1.87 Å
R-free 0.206
|
|
4Z83
PKAB3 in complex with pyrrolidine inhibitor 47a
Deposited 2015-04-08
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain I
6–25(20 aa)
|
Not recorded
|
4L7 7-{(3S,4R)-4-[(5-bromothiophen-2-yl)carbonyl]pyrrolidin-3-yl}quinazolin-4(3H)-one × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 7;277 K;The droplets, containing 16 mg/ml PKAB3, 25 mM Bis-Tris-HCl, pH 7.0, 150 mM KCl, 1.5mM octanoyl-N-methylglucamide and 0.8 mM PKI peptide, were equilibrated against 12-26 % (v/v) methanol.
|
Resolution 1.80 Å
R-free 0.217
|
|
4Z84
PKAB3 in complex with pyrrolidine inhibitor 34a
Deposited 2015-04-08
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain I
6–25(20 aa)
|
Not recorded
|
NVX 7-[(3S,4R)-4-(3-chlorophenyl)carbonylpyrrolidin-3-yl]-3H-quinazolin-4-one × 1
MOH METHANOL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7;277 K;The droplets, containing 16 mg/ml protein 25 mM Bis-Tris-HCl, pH 7.0, 150 mM KCl, 1.5mM octanoyl-N-methylglucamide, 0.8 mM PKI peptide and 1mM of the pyrrolidine inhibitor 34a, were equilibrated against 12-26 % (v/v) methanol.
|
Resolution 1.55 Å
R-free 0.234
|
|
5BX6
PKA in complex with a halogenated phthalazinone fragment compound.
Deposited 2015-06-08
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain B
6–25(20 aa)
Fragment:UNP residues 6-25
|
Not recorded
|
495 4-chlorophthalazin-1(2H)-one × 1
MPD (4S)-2-METHYL-2,4-PENTANEDIOL × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7;277 K;The droplets, containing 10 mg/ml PKA.
25 mM Bis-Tris-HCl, pH 7.0, 150 mM KCl, 1.5mM octanoyl-N-methylglucamide and 0.8 mM PKI peptide, were equilibrated against 12-26 % (v/v) methanol.
|
Resolution 1.89 Å
R-free 0.218
|
|
5BX7
PKA in complex with a benzothiophene fragment compound.
Deposited 2015-06-08
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain B
6–25(20 aa)
Fragment:UNP residues 6-25
|
Not recorded
|
4W1 1-benzothiophen-3-ylmethanol × 1
MPD (4S)-2-METHYL-2,4-PENTANEDIOL × 2
EDO 1,2-ETHANEDIOL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7;277 K;The droplets, containing 10 mg/ml PKA.
25 mM Bis-Tris-HCl, pH 7.0, 150 mM KCl, 1.5mM octanoyl-N-methylglucamide and 0.8 mM PKI peptide, were equilibrated against 12-26 % (v/v) methanol.
|
Resolution 1.89 Å
R-free 0.226
|
|
5LCP
Cocrystal structure of cAMP-dependent Protein Kinase (PKA) in complex with Fasudil (M77)
Deposited 2016-06-22
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain B
6–25(20 aa)
|
Not recorded
|
M77 5-(1,4-DIAZEPAN-1-SULFONYL)ISOQUINOLINE × 1
MOH METHANOL × 5
DMS DIMETHYL SULFOXIDE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 6.9;277.15 K;Drop:
10 mg/ml PKA (0.240 mM)
30 mM MBT (MES/Bis-Tris Puffer pH 6.9)
1 mM DTT
0.1 mM EDTA
75 mM LiCl
0.03 mM Mega 8
0.07mM PKI (Sigma: P7739)
1.2 mM ligand solved in DMSO (50 mM Stock)
Reservoir: 18% Methanol
0.003 mL drop volume, 0.4 mL reservoir volume
|
Resolution 1.43 Å
R-free 0.166
|
|
5LCQ
Cocrystal structure of cAMP-dependent Protein Kinase (PKA) in complex with long-chain Fasudil-derivative (Ligand 05)
Deposited 2016-06-22
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain B
6–25(20 aa)
|
Not recorded
|
6TV ~{N}-[2-(propylamino)ethyl]isoquinoline-5-sulfonamide × 1
MRD (4R)-2-METHYLPENTANE-2,4-DIOL × 1
MOH METHANOL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 6.9;277.15 K;Drop:
10 mg/ml PKA (0.240 mM)
30 mM MBT (MES/Bis-Tris Puffer pH 6.9)
1 mM DTT
0.1 mM EDTA
75 mM LiCl
0.03 mM Mega 8
0.07mM PKI (Sigma: P7739)
1.2 mM ligand solved in DMSO (50 mM Stock)
Reservoir: 18% Methanol
0.003 mL drop volume, 0.4 mL reservoir volume
|
Resolution 1.42 Å
R-free 0.171
|
|
5LCR
Cocrystal structure of cAMP-dependent Protein Kinase (PKA) in complex with open-chain Fasudil-derivative (Ligand 04)
Deposited 2016-06-22
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain B
6–25(20 aa)
|
Not recorded
|
6TX 2-[isoquinolin-5-ylsulfonyl(propyl)amino]ethylazanium × 1
MRD (4R)-2-METHYLPENTANE-2,4-DIOL × 1
MOH METHANOL × 5
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 6.9;277.15 K;Drop:
10 mg/ml PKA (0.240 mM)
30 mM MBT (MES/Bis-Tris Puffer pH 6.9)
1 mM DTT
0.1 mM EDTA
75 mM LiCl
0.03 mM Mega 8
0.07mM PKI (Sigma: P7739)
1.2 mM ligand solved in DMSO (100 mM Stock)
Reservoir: 14% Methanol
0.003 mL drop volume, 0.4 mL reservoir volume
|
Resolution 1.56 Å
R-free 0.197
|
|
5LCT
Cocrystal structure of cAMP-dependent Protein Kinase (PKA) in complex with a R-methyl-piperazine substituted Fasudil-derivative (Ligand 02)
Deposited 2016-06-22
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain B
6–25(20 aa)
|
Not recorded
|
6TY 5-[(2~{R})-2-methylpiperazin-1-yl]sulfonylisoquinoline × 1
MPD (4S)-2-METHYL-2,4-PENTANEDIOL × 1
MOH METHANOL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 6.9;277.15 K;Drop:
10 mg/ml PKA (0.240 mM)
30 mM MBT (MES/Bis-Tris Puffer pH 6.9)
1 mM DTT
0.1 mM EDTA
75 mM LiCl
0.03 mM Mega 8
0.07mM PKI (Sigma: P7739)
1.2 mM ligand solved in DMSO (50 mM Stock)
Reservoir: 19% Methanol
0.003 mL drop volume, 0.4 mL reservoir volume
|
Resolution 1.61 Å
R-free 0.174
|
|
5LCU
Cocrystal structure of cAMP-dependent Protein Kinase (PKA) in complex with a S-methyl-piperazine substituted Fasudil-derivative (Ligand 01)
Deposited 2016-06-22
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain B
6–25(20 aa)
|
Not recorded
|
IQP 1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE × 1
MOH METHANOL × 3
MPD (4S)-2-METHYL-2,4-PENTANEDIOL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 6.9;277.15 K;Drop:
10 mg/ml PKA (0.240 mM)
30 mM MBT (MES/Bis-Tris Puffer pH 6.9)
1 mM DTT
0.1 mM EDTA
75 mM LiCl
0.03 mM Mega 8
0.07mM PKI (Sigma: P7739)
1.2 mM ligand solved in DMSO (50 mM Stock)
Reservoir: 16% Methanol
0.003 mL drop volume, 0.4 mL reservoir volume
|
Resolution 1.58 Å
R-free 0.192
|
|
5M0B
Cocrystal structure of cAMP-dependent Protein Kinase (PKA) in complex with a short-chained N-(2-aminoethyl)isoquinoline-5-sulfonamide) Fasudil-derivative (Ligand 03)
Deposited 2016-10-04
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain B
6–25(20 aa)
|
Not recorded
|
IQU N-(2-AMINOETHYL)ISOQUINOLINE-5-SULFONAMIDE × 1
MPD (4S)-2-METHYL-2,4-PENTANEDIOL × 1
MOH METHANOL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 6.9;277.15 K;Drop:
10 mg/ml PKA (0.240 mM)
30 mM MBT (MES/Bis-Tris Puffer pH 6.9)
1 mM DTT
0.1 mM EDTA
75 mM LiCl
0.03 mM Mega 8
0.07mM PKI (Sigma: P7739)
1.2 mM ligand solved in DMSO (50 mM Stock)
Reservoir: 18% Methanol
0.003 mL drop volume, 0.4 mL reservoir volume
|
Resolution 1.51 Å
R-free 0.159
|
|
5M0C
Cocrystal structure of cAMP-dependent Protein Kinase (PKA) in complex with the Fasudil-fragment isoquinoline-5-sulfonamide
Deposited 2016-10-04
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain B
6–25(20 aa)
|
Not recorded
|
7CB isoquinoline-5-sulfonamide × 1
MRD (4R)-2-METHYLPENTANE-2,4-DIOL × 1
DMS DIMETHYL SULFOXIDE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 6.9;277.15 K;Drop:
10 mg/ml PKA (0.240 mM)
30 mM MBT (MES/Bis-Tris Puffer pH 6.9)
1 mM DTT
0.1 mM EDTA
75 mM LiCl
0.03 mM Mega 8
0.07mM PKI (Sigma: P7739)
0.12 mM ligand solved in DMSO (100 mM Stock)
Reservoir: 14% Methanol
0.003 mL drop volume, 0.4 mL reservoir volume
|
Resolution 1.73 Å
R-free 0.200
|
|
5M0L
Cocrystal structure of cAMP-dependent Protein Kinase (PKA) in complex with the methylated Fasudil-derived fragment N-methylisoquinoline-5-sulfonamide (Ligand 02)
Deposited 2016-10-05
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain B
6–25(20 aa)
|
Not recorded
|
7CT ~{N}-methylisoquinoline-5-sulfonamide × 2
MPD (4S)-2-METHYL-2,4-PENTANEDIOL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 6.9;277.15 K;Drop:
10 mg/ml PKA (0.240 mM)
30 mM MBT (MES/Bis-Tris Puffer pH 6.9)
1 mM DTT
0.1 mM EDTA
75 mM LiCl
0.03 mM Mega 8
0.07mM PKI (Sigma: P7739)
1.2 mM ligand solved in DMSO (100 mM Stock)
Reservoir: 16% Methanol
0.003 mL drop volume, 0.4 mL reservoir volume
|
Resolution 1.47 Å
R-free 0.173
|
|
5M0U
Apostructure structure of cAMP-dependent Protein Kinase (PKA) from CHO cells with a peptidic inhibitor fragment
Deposited 2016-10-05
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain B
6–25(20 aa)
|
Not recorded
|
MOH METHANOL × 9
MRD (4R)-2-METHYLPENTANE-2,4-DIOL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 6.9;277.15 K;10 mg/ml PKA (0.240 mM)
30 mM MBT (MES/Bis-Tris Puffer pH 6.9)
1 mM DTT
0.1 mM EDTA
75 mM LiCl
0.03 mM Mega 8
0.07mM PKI (Sigma: P7739)
Reservoir: 23% Methanol
0.003 mL drop volume, 0.4 mL reservoir volume
|
Resolution 1.67 Å
R-free 0.189
|
|
5M6V
Cocrystal structure of cAMP-dependent Protein Kinase (PKA) in complex with a double methylated Fasudil-derivative
Deposited 2016-10-26
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain B
6–25(20 aa)
Fragment:UNP residues 6-25
|
Not recorded
|
H52 (S)-2-METHYL-1-[(4-METHYL-5-ISOQUINOLINE)SULFONYL]-HOMOPIPERAZINE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 6.9;277.15 K;Drop:
10 mg/ml PKA (0.240 mM)
30 mM MBT (MES/Bis-Tris Puffer pH 6.9)
1 mM DTT
0.1 mM EDTA
75 mM LiCl
0.03 mM Mega 8
0.07mM PKI (Sigma: P7739)
1.2 mM ligand solved in DMSO (50 mM Stock)
Reservoir: 18% Methanol
0.003 mL drop volume, 0.4 mL reservoir volume
|
Resolution 1.42 Å
R-free 0.174
|
|
5M6Y
Cocrystal structure of cAMP-dependent Protein Kinase (PKA) in complex with a methylisoquinoline Fasudil-derivative
Deposited 2016-10-26
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain B
6–25(20 aa)
Fragment:UNP Residues 6-25
|
Not recorded
|
7KB 5-(1,4-diazepan-1-ylsulfonyl)-4-methyl-isoquinoline × 1
MPD (4S)-2-METHYL-2,4-PENTANEDIOL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 6.9;277.15 K;Drop:
10 mg/ml PKA (0.240 mM)
30 mM MBT (MES/Bis-Tris Puffer pH 6.9)
1 mM DTT
0.1 mM EDTA
75 mM LiCl
0.03 mM Mega 8
0.07mM PKI (Sigma: P7739)
1.2 mM ligand solved in DMSO (50 mM Stock)
Reservoir: 20% Methanol
0.003 mL drop volume, 0.4 mL reservoir volume
|
Resolution 1.37 Å
R-free 0.166
|
|
5M71
Cocrystal structure of cAMP-dependent Protein Kinase (PKA) in complex with an (R)-methyl substitued Fasudil-derivative.
Deposited 2016-10-26
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain B
6–25(20 aa)
|
Not recorded
|
7K7 5-[[(2~{R})-2-methyl-1,4-diazepan-4-ium-1-yl]sulfonyl]isoquinoline × 1
MOH METHANOL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 6.9;277.15 K;Drop:
10 mg/ml PKA (0.240 mM)
30 mM MBT (MES/Bis-Tris Puffer pH 6.9)
1 mM DTT
0.1 mM EDTA
75 mM LiCl
0.03 mM Mega 8
0.07mM PKI (Sigma: P7739)
1.2 mM ligand solved in DMSO (50 mM Stock)
Reservoir: 19% Methanol
0.003 mL drop volume, 0.4 mL reservoir volume
|
Resolution 1.49 Å
R-free 0.176
|
|
5M75
Cocrystal structure of cAMP-dependent Protein Kinase (PKA) in complex with a (S)-methyl substitued Fasudil-derivative
Deposited 2016-10-26
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain B
6–25(20 aa)
|
Not recorded
|
DMS DIMETHYL SULFOXIDE × 1
9K6 5-[[(2~{S})-2-methyl-1,4-diazepan-1-yl]sulfonyl]isoquinoline × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 6.9;277.15 K;Drop:
10 mg/ml PKA (0.240 mM)
30 mM MBT (MES/Bis-Tris Puffer pH 6.9)
1 mM DTT
0.1 mM EDTA
75 mM LiCl
0.03 mM Mega 8
0.07mM PKI (Sigma: P7739)
1.2 mM ligand solved in DMSO (50 mM Stock)
Reservoir: 18% Methanol
0.003 mL drop volume, 0.4 mL reservoir volume
|
Resolution 1.54 Å
R-free 0.174
|
|
5N23
Protein kinase A mutants as surrogate model for Aurora B with AT9283 inhibitor
Deposited 2017-02-07
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain B
6–25(20 aa)
|
Not recorded
|
35R 1-cyclopropyl-3-{3-[5-(morpholin-4-ylmethyl)-1H-benzimidazol-2-yl]-1H-pyrazol-4-yl}urea × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7.5;277.15 K;12-26 % (v/v) methanol
|
Resolution 2.09 Å
R-free 0.239
|
|
6E99
Crystal structure of Protein Kinase A in complex with the PKI peptide and an amino-pyridinylbenzamide based inhibitor.
Deposited 2018-07-31
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain B
6–23(18 aa)
|
Not recorded
|
J0G 2-[(2-aminoethyl)amino]-N-[(1R)-1-(3-methoxyphenyl)ethyl]-4-(pyridin-4-yl)benzamide × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 6.6;277 K;5 to 27% methanol
|
Resolution 1.88 Å
R-free 0.230
|
|
6E9L
Crystal structure of Protein Kinase A in complex with the PKI peptide and a pyridinylbenzamide based inhibitor
Deposited 2018-08-01
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain B
6–23(18 aa)
|
Not recorded
|
J0P N-[(2,3-dihydro-1,4-benzodioxin-5-yl)methyl]-4-(pyridin-4-yl)benzamide × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 6.6;277 K;5 to 27% Methanol
|
Resolution 2.80 Å
R-free 0.271
|
|
6FRX
PKA variant as Aurora B mimic in complex with a dianilinopyrimidine inhibitor
Deposited 2018-02-16
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain B
6–25(20 aa)
|
Not recorded
|
E3Z ~{N}-[3-[(5-chloranyl-2-phenylazanyl-pyrimidin-4-yl)amino]phenyl]prop-2-enamide × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;277 K;PKA-AU6 at 10mg/ml in 25mM BisTRIS/HCl (pH7.0), 150mM KCl, 1.5mM octanoyl-N-methylglucamide and 0.8mM PKI was equilibrated against 12-26% (v/v) methanol.
|
Resolution 1.88 Å
R-free 0.226
|
|
6QJ7
Difluorophenyl diacylhydrazides: Potent inhibitors of Serum- and Glucocorticoid-inducible Kinase 1 (SGK1)
Deposited 2019-01-23
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain B
6–25(20 aa)
|
Not recorded
|
J4B ~{N}'-[(2~{S})-2-[3,5-bis(fluoranyl)phenyl]-2-oxidanyl-ethanoyl]-2-ethyl-3-methyl-4-oxidanyl-benzohydrazide × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;293 K;5mM MES, 5mM Bis-Tris-propane, 75mM LiCl, 1mM DTT, 0.1mM EDTA, 1.4mM PKA-peptide, 1.4mM MEGA-8, 14% Et-OH as well solution
|
Resolution 1.69 Å
R-free 0.214
|
|
6X2U
Crystal Structure of PKINES peptide bound to CRM1
Deposited 2020-05-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 4
PDB declaration: tetrameric
|
Chain D
34–49(16 aa)
Fragment:residues 34-49
|
Not recorded
|
GNP PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER × 1
MG MAGNESIUM ION × 1
GOL GLYCEROL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;273 K;17% (weight/vol) PEG3350, 100 mM Bis-Tris (pH 6.4), 200 mM ammonium nitrate, and 10 mM Spermine HCl
|
Resolution 2.20 Å
R-free 0.240
|
|
6X2V
Crystal Structure of PKI(DE)NES peptide bound to CRM1
Deposited 2020-05-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 4
PDB declaration: tetrameric
|
Chain D
34–49(16 aa)
Fragment:residues 34-49
|
Mutation:N48D, K49E
|
GNP PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER × 1
MG MAGNESIUM ION × 1
GOL GLYCEROL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;273 K;17% (weight/vol) PEG3350, 100 mM Bis-Tris (pH 6.4), 200 mM ammonium nitrate, and 10 mM Spermine HCl
|
Resolution 2.82 Å
R-free 0.262
|
|
6X2W
Crystal Structure of PKINES peptide bound to CRM1(E571K)
Deposited 2020-05-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 4
PDB declaration: tetrameric
|
Chain D
35–49(15 aa)
Fragment:residues 35-49
|
Not recorded
|
GNP PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER × 1
MG MAGNESIUM ION × 1
GOL GLYCEROL × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;273 K;17% (weight/vol) PEG3350, 100 mM Bis-Tris (pH 6.4), 200 mM ammonium nitrate, and 10 mM Spermine HCl
|
Resolution 3.00 Å
R-free 0.253
|
|
7UJX
Structure of cAMP-dependent protein kinase using a MD-MX procedure, produced using 2.4 Angstrom data
Deposited 2022-03-31
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain I
6–24(19 aa)
|
Not recorded
|
ADP ADENOSINE-5'-DIPHOSPHATE × 1
PO4 PHOSPHATE ION × 2
MG MAGNESIUM ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 6.5;293 K;20% PEG 4000, 0.05 M MES pH 5.2, 0.05 M MgCl2, and 0.005 M DTT
|
Resolution 2.40 Å
R-free 0.176
|
|
7V0G
Structure of cAMP-dependent protein kinase using a MD-MX procedure, produced using 1.63 Angstrom data
Deposited 2022-05-10
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain I
6–24(19 aa)
|
Not recorded
|
ADP ADENOSINE-5'-DIPHOSPHATE × 1
PO4 PHOSPHATE ION × 2
MG MAGNESIUM ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 6.5;293 K;20% PEG 4000, 0.05 M MES pH 5.2, 0.05 M MgCl2, and 0.005 M DTT
|
Resolution 1.63 Å
R-free 0.163
|
|
8FE2
Structure of J-PKAc chimera complexed with Aplithianine A
Deposited 2022-12-05
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain I
6–25(20 aa)
|
Not recorded
|
XTI 6-[(6M)-6-(1-methyl-1H-imidazol-5-yl)-2,3-dihydro-4H-1,4-thiazin-4-yl]-9H-purine × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7.5;277.15 K;200 mM Lithium sulfate, 100 mM HEPES 7.5, 20% PEG 3350
|
Resolution 2.34 Å
R-free 0.251
|
|
8FE2
Structure of J-PKAc chimera complexed with Aplithianine A
Deposited 2022-12-05
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Insufficient information
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain J
6–25(20 aa)
|
Not recorded
|
XTI 6-[(6M)-6-(1-methyl-1H-imidazol-5-yl)-2,3-dihydro-4H-1,4-thiazin-4-yl]-9H-purine × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7.5;277.15 K;200 mM Lithium sulfate, 100 mM HEPES 7.5, 20% PEG 3350
|
Resolution 2.34 Å
R-free 0.251
|
|
8FE5
Structure of J-PKAc chimera complexed with Aplithianine B
Deposited 2022-12-05
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain I
6–25(20 aa)
|
Not recorded
|
XTT 6-[(6P)-6-(1-methyl-1H-imidazol-5-yl)-2,3-dihydro-4H-1,4-thiazin-4-yl]-7,9-dihydro-8H-purin-8-one × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7.5;277.15 K;200 mM Lithium Sulfate, 100 mM HEPES 7.5, 25% PEG 3350
|
Resolution 2.51 Å
R-free 0.243
|
|
8FE5
Structure of J-PKAc chimera complexed with Aplithianine B
Deposited 2022-12-05
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Insufficient information
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain J
6–25(20 aa)
|
Not recorded
|
XTT 6-[(6P)-6-(1-methyl-1H-imidazol-5-yl)-2,3-dihydro-4H-1,4-thiazin-4-yl]-7,9-dihydro-8H-purin-8-one × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7.5;277.15 K;200 mM Lithium Sulfate, 100 mM HEPES 7.5, 25% PEG 3350
|
Resolution 2.51 Å
R-free 0.243
|
|
8FEC
Structure of J-PKAc chimera complexed with Aplithianine derivative
Deposited 2022-12-06
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain I
6–25(20 aa)
|
Not recorded
|
XU0 6-[(6P)-6-(4-bromo-1-methyl-1H-imidazol-5-yl)-2,3-dihydro-4H-1,4-thiazin-4-yl]-7H-purine × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7.5;277.15 K;200 mM Lithium sulfate, 100 mM HEPES 7.5, 25% PEG 3350
|
Resolution 2.70 Å
R-free 0.287
|
|
8FEC
Structure of J-PKAc chimera complexed with Aplithianine derivative
Deposited 2022-12-06
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Insufficient information
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain J
6–25(20 aa)
|
Not recorded
|
XU0 6-[(6P)-6-(4-bromo-1-methyl-1H-imidazol-5-yl)-2,3-dihydro-4H-1,4-thiazin-4-yl]-7H-purine × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7.5;277.15 K;200 mM Lithium sulfate, 100 mM HEPES 7.5, 25% PEG 3350
|
Resolution 2.70 Å
R-free 0.287
|
|
9DC6
Structure of J-PKAc chimera in complex with Aplithianine e1
Deposited 2024-08-25
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain I
6–25(20 aa)
|
Not recorded
|
A1A3I N-(2-aminoethyl)-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-3,4-dihydro-2H-1,4-thiazine-6-carboxamide × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7.5;277.15 K;200 mM Lithium sulfate, 100 mM Hepes pH 7.5, 20 % PEG 3350
|
Resolution 2.70 Å
R-free 0.311
|
|
9DC6
Structure of J-PKAc chimera in complex with Aplithianine e1
Deposited 2024-08-25
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain J
6–25(20 aa)
|
Not recorded
|
A1A3I N-(2-aminoethyl)-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-3,4-dihydro-2H-1,4-thiazine-6-carboxamide × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7.5;277.15 K;200 mM Lithium sulfate, 100 mM Hepes pH 7.5, 20 % PEG 3350
|
Resolution 2.70 Å
R-free 0.311
|
|
9DCD
Structure of J-PKAc chimera in complex with Aplithianine d2
Deposited 2024-08-25
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain I
6–25(20 aa)
|
Not recorded
|
A1A3J N-(2-aminoethyl)-4-(7H-purin-6-yl)-3,4-dihydro-2H-1,4-thiazine-6-carboxamide × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION;pH 6;277.15 K;0.2 M LiCl, 0.1 M Mes pH:6.0, 20% PEG 6000
|
Resolution 2.70 Å
R-free 0.191
|
|
9NFS
Structure of J-PKAc chimera in complex with Aplithianine j1
Deposited 2025-02-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain D
6–25(20 aa)
|
Not recorded
|
A1BX1 (4P)-4-[4-(pyrimidin-4-yl)-3,4-dihydro-2H-1,4-thiazin-6-yl]-1H-pyrrolo[2,3-b]pyridine × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7.6;277.15 K;0.2 M LiCl, 0.1 M hopes, pH 7.6, 25% PEG 3350
|
Resolution 2.45 Å
R-free 0.334
|
|
9NFS
Structure of J-PKAc chimera in complex with Aplithianine j1
Deposited 2025-02-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Insufficient information
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain C
6–25(20 aa)
|
Not recorded
|
A1BX1 (4P)-4-[4-(pyrimidin-4-yl)-3,4-dihydro-2H-1,4-thiazin-6-yl]-1H-pyrrolo[2,3-b]pyridine × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7.6;277.15 K;0.2 M LiCl, 0.1 M hopes, pH 7.6, 25% PEG 3350
|
Resolution 2.45 Å
R-free 0.334
|
|
9PC1
Co-crystal structure of the cAMP-dependent protein kinase catalytic subunit alpha with the inhibitor BLU0588
Deposited 2025-06-26
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain I
6–24(19 aa)
|
Not recorded
|
MPD (4S)-2-METHYL-2,4-PENTANEDIOL × 1
A1CHQ (6M)-N-[(1R,2R)-2-(pyrrolidin-1-yl)-2,3-dihydro-1H-inden-1-yl]-6-(1H-pyrrolo[2,3-b]pyridin-4-yl)pyridine-3-carboxamide × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;277 K;10% MPD, Hepes pH7, 10% Methanol
|
Resolution 1.55 Å
R-free 0.214
|